The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1O43OJ     2-[[(2-amino-1,3-thiazol-4- yl)-[[(2S,3S)-1...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of aztreonam


High impact information on aztreonam

  • Immediate hypersensitivity to aztreonam [6].
  • We demonstrate that our error-prone Pol I can be used to generate enzymes with distinct properties by generating TEM-1 beta-lactamase mutants able to hydrolyze a third-generation lactam antibiotic, aztreonam [7].
  • Because the use of aztreonam as the initial empirical treatment requires a concomitant antibiotic against gram-positive infections and the possibility of streptococcal superinfections, cefotaxime seems to be a more advantageous therapeutic alternative for this patient population [8].
  • Streptococcal superinfections developed in three patients (14.2%) in the aztreonam group [8].
  • In the remaining patients, signs and symptoms of infection were promptly controlled, and ascitic fluid cultures became negative after 48 hr in all cases, except in one patient from the aztreonam group, who was a clinical failure [8].

Chemical compound and disease context of aztreonam


Biological context of aztreonam


Anatomical context of aztreonam


Associations of aztreonam with other chemical compounds


Gene context of aztreonam


Analytical, diagnostic and therapeutic context of aztreonam

  • MAIN OUTCOME MEASURE--We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo [29].
  • Aztreonam, for example, is active against most gram-negative pathogenic bacteria and has been evaluated in several clinical trials in neutropenic patients [30].
  • None of 41 patients with documented IgE-reactive skin tests to various penicillin determinants concurrently demonstrated reproducible reactivity to any aztreonam reagents [31].
  • Multicenter trials were conducted to determine the safety and efficacy of aztreonam in the treatment of patients with gram-negative bacterial infections [32].
  • High-pressure liquid chromatographic (HPLC) systems were developed for the quantitative analysis of aztreonam in human, monkey, rat, mouse, and rabbit sera and urine [33].


  1. Aztreonam for cystic fibrosis patients who are hypersensitive to other beta-lactams. Jensen, T., Koch, C., Pedersen, S.S., Høiby, N. Lancet (1987) [Pubmed]
  2. Aztreonam in CAPD peritonitis. Dratwa, M., Glupczynski, Y., Lameire, N., Matthys, D., Verschraegen, G., van Eeckhoute, M., Boelaert, J., Schurgers, M., van Landuyt, H., Verbeelen, D. Lancet (1987) [Pubmed]
  3. Aztreonam compared with gentamicin for treatment of serious urinary tract infections. Sattler, F.R., Moyer, J.E., Schramm, M., Lombard, J.S., Appelbaum, P.C. Lancet (1984) [Pubmed]
  4. Aztreonam failure in typhoid fever. Choo, K.E., Ariffin, W.A., Ong, K.H., Sivakumaran, S. Lancet (1991) [Pubmed]
  5. Aztreonam-induced anaphylaxis. Iglesias Cadarso, A., Sáez Jiménez, S.A., Vidal Pan, C., Rodriguez Mosquera, M. Lancet (1990) [Pubmed]
  6. Immediate hypersensitivity to aztreonam. Soto Alvarez, J., Sacristán del Castillo, J.A., Sampedro García, I., Alsar Ortiz, M.J. Lancet (1990) [Pubmed]
  7. Targeted gene evolution in Escherichia coli using a highly error-prone DNA polymerase I. Camps, M., Naukkarinen, J., Johnson, B.P., Loeb, L.A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  8. Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. Ariza, J., Xiol, X., Esteve, M., Fernández Bañeres, F., Liñares, J., Alonso, T., Gudiol, F. Hepatology (1991) [Pubmed]
  9. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Schentag, J.J., Vari, A.J., Winslade, N.E., Swanson, D.J., Smith, I.L., Simons, G.W., Vigano, A. Am. J. Med. (1985) [Pubmed]
  10. Aztreonam in the treatment of urinary tract infection. Childs, S.J. Am. J. Med. (1985) [Pubmed]
  11. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Quinn, J.P., Miyashiro, D., Sahm, D., Flamm, R., Bush, K. Antimicrob. Agents Chemother. (1989) [Pubmed]
  12. Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Loewenstein, A., Zemel, E., Lazar, M., Perlman, I. Invest. Ophthalmol. Vis. Sci. (1993) [Pubmed]
  13. Multiply resistant mutants of Enterobacter cloacae selected by beta-lactam antibiotics. Then, R.L., Angehrn, P. Antimicrob. Agents Chemother. (1986) [Pubmed]
  14. Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime. Cantu, C., Huang, W., Palzkill, T. J. Biol. Chem. (1996) [Pubmed]
  15. Review of the clinical pharmacology of the monobactam antibiotic aztreonam. Swabb, E.A. Am. J. Med. (1985) [Pubmed]
  16. Clinical pharmacokinetics of aztreonam. An update. Mattie, H. Clinical pharmacokinetics. (1994) [Pubmed]
  17. Metabolism and pharmacokinetics of aztreonam in healthy subjects. Swabb, E.A., Singhvi, S.M., Leitz, M.A., Frantz, M., Sugerman, A. Antimicrob. Agents Chemother. (1983) [Pubmed]
  18. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Castanheira, M., Toleman, M.A., Jones, R.N., Schmidt, F.J., Walsh, T.R. Antimicrob. Agents Chemother. (2004) [Pubmed]
  19. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. LeFrock, J.L., Smith, B.R., Chandrasekar, P., Rolston, K.V., Molavi, A., Kannangara, W. Arch. Intern. Med. (1987) [Pubmed]
  20. Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis. Modai, J., Vittecoq, D., Decazes, J.M., Wolff, M., Meulemans, A. Antimicrob. Agents Chemother. (1986) [Pubmed]
  21. Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges. Duma, R.J., Berry, A.J., Smith, S.M., Baggett, J.W., Swabb, E.A., Platt, T.B. Antimicrob. Agents Chemother. (1984) [Pubmed]
  22. Mutations altering substrate specificity in OHIO-1, and SHV-1 family beta-lactamase. Shlaes, D.M., Currie-McCumber, C. Biochem. J. (1992) [Pubmed]
  23. Influence of beta-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli. Suerbaum, S., Leying, H., Kroll, H.P., Gmeiner, J., Opferkuch, W. Antimicrob. Agents Chemother. (1987) [Pubmed]
  24. Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase. Barlow, M., Hall, B.G. Genetics (2002) [Pubmed]
  25. Continuous antibiotic treatment for experimental abdominal sepsis: effects on organ inflammatory cytokine expression and neutrophil sequestration. Mercer-Jones, M.A., Hadjiminas, D.J., Heinzelmann, M., Peyton, J., Cook, M., Cheadle, W.G. The British journal of surgery. (1998) [Pubmed]
  26. AmpC and AmpH, proteins related to the class C beta-lactamases, bind penicillin and contribute to the normal morphology of Escherichia coli. Henderson, T.A., Young, K.D., Denome, S.A., Elf, P.K. J. Bacteriol. (1997) [Pubmed]
  27. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors. Brun, T., Péduzzi, J., Caniça, M.M., Paul, G., Névot, P., Barthélémy, M., Labia, R. FEMS Microbiol. Lett. (1994) [Pubmed]
  28. Involvement of N-acetylmuramyl-L-alanine amidases in cell separation and antibiotic-induced autolysis of Escherichia coli. Heidrich, C., Templin, M.F., Ursinus, A., Merdanovic, M., Berger, J., Schwarz, H., de Pedro, M.A., Höltje, J.V. Mol. Microbiol. (2001) [Pubmed]
  29. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. DuPont, H.L., Ericsson, C.D., Mathewson, J.J., de la Cabada, F.J., Conrad, D.A. JAMA (1992) [Pubmed]
  30. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients. Rolston, K.V., Bodey, G.P., Elting, L. Am. J. Med. (1990) [Pubmed]
  31. Investigation into the immunologic cross-reactivity of aztreonam with other beta-lactam antibiotics. Saxon, A., Swabb, E.A., Adkinson, N.F. Am. J. Med. (1985) [Pubmed]
  32. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. Henry, S.A., Bendush, C.B. Am. J. Med. (1985) [Pubmed]
  33. High-pressure liquid chromatographic analysis of aztreonam in sera and urine. Pilkiewicz, F.G., Remsburg, B.J., Fisher, S.M., Sykes, R.B. Antimicrob. Agents Chemother. (1983) [Pubmed]
WikiGenes - Universities